KR100989029B1 - 세포 증식 억제제로서의 퀴놀론 동족체 - Google Patents

세포 증식 억제제로서의 퀴놀론 동족체 Download PDF

Info

Publication number
KR100989029B1
KR100989029B1 KR1020077008765A KR20077008765A KR100989029B1 KR 100989029 B1 KR100989029 B1 KR 100989029B1 KR 1020077008765 A KR1020077008765 A KR 1020077008765A KR 20077008765 A KR20077008765 A KR 20077008765A KR 100989029 B1 KR100989029 B1 KR 100989029B1
Authority
KR
South Korea
Prior art keywords
compound
ring
alkyl
mmol
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077008765A
Other languages
English (en)
Korean (ko)
Other versions
KR20070085264A (ko
Inventor
제프리 피 휘튼
파브리스 피에르
콜린 레간
마이클 슈웨브
조지 페트로스 이안니코우로스
마이클 정
조니 와이 나가사와
피터 추아
Original Assignee
사일린 파마슈티칼스, 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/149,007 external-priority patent/US7652134B2/en
Application filed by 사일린 파마슈티칼스, 인크 filed Critical 사일린 파마슈티칼스, 인크
Publication of KR20070085264A publication Critical patent/KR20070085264A/ko
Application granted granted Critical
Publication of KR100989029B1 publication Critical patent/KR100989029B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020077008765A 2004-09-17 2005-09-16 세포 증식 억제제로서의 퀴놀론 동족체 Expired - Fee Related KR100989029B1 (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US61103004P 2004-09-17 2004-09-17
US60/611,030 2004-09-17
US63860304P 2004-12-22 2004-12-22
US60/638,603 2004-12-22
US68898605P 2005-06-09 2005-06-09
US68879605P 2005-06-09 2005-06-09
US60/688,986 2005-06-09
US11/149,007 US7652134B2 (en) 2004-09-17 2005-06-09 Methods for converting quinolone esters into quinolone amides
US60/688,796 2005-06-09
US11/149,007 2005-06-09

Publications (2)

Publication Number Publication Date
KR20070085264A KR20070085264A (ko) 2007-08-27
KR100989029B1 true KR100989029B1 (ko) 2010-10-25

Family

ID=35735203

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077008765A Expired - Fee Related KR100989029B1 (ko) 2004-09-17 2005-09-16 세포 증식 억제제로서의 퀴놀론 동족체

Country Status (11)

Country Link
US (1) US7816406B2 (https=)
EP (1) EP1802306A2 (https=)
JP (1) JP2008513485A (https=)
KR (1) KR100989029B1 (https=)
AU (1) AU2005286965B2 (https=)
BR (1) BRPI0515319A (https=)
CA (1) CA2580749C (https=)
IL (1) IL181857A0 (https=)
MX (1) MX2007003282A (https=)
NZ (1) NZ553746A (https=)
WO (1) WO2006034113A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1928887B1 (en) 2005-08-05 2014-12-17 Senhwa Biosciences, Inc. Methods of preparing quinolone analogs
WO2007146831A2 (en) * 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
WO2007146813A2 (en) * 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Pyridinone analogs as cell proliferation inhibitors
US7956064B2 (en) 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
US20080318939A1 (en) * 2007-06-22 2008-12-25 Whitten Jeffrey P Methods for treating ophthalmic disorders
CN101801190A (zh) * 2007-06-22 2010-08-11 赛林药物股份有限公司 治疗异常细胞增殖性疾病的方法
WO2009097014A2 (en) * 2007-08-31 2009-08-06 Cylene Pharmaceuticals, Inc. Therapeutic kinase modulators
EP2201010B1 (en) 2007-09-14 2013-11-06 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
PL3092901T3 (pl) * 2007-10-05 2020-10-19 Senhwa Biosciences, Inc. Analogi chinolonu i sposoby z nimi związane
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
RU2435758C1 (ru) * 2010-07-19 2011-12-10 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) Способ получения этилового эфира 3-оксо-3-(2,6-дихлорпиридин-3-ил) пропановой кислоты
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
PL3140305T3 (pl) 2014-05-09 2018-10-31 Pimera, Inc. Nowe kompozycje, ich zastosowania i sposoby wytwarzania
WO2016137471A1 (en) * 2015-02-26 2016-09-01 Nantpharma, Llc Method for enhanced heparin quality
WO2017087235A1 (en) 2015-11-20 2017-05-26 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
JP2018537486A (ja) * 2015-12-14 2018-12-20 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
CA3057741A1 (en) 2017-03-28 2018-10-04 Pimera, Inc. Novel crystal forms of a pol1 inhibitor
TWI884912B (zh) 2018-02-15 2025-06-01 生華生物科技股份有限公司 喹啉酮類似物及其鹽、組合物及其使用方法
JP2020189888A (ja) * 2020-08-28 2020-11-26 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
WO2025114459A1 (en) * 2023-11-28 2025-06-05 Genome Therapeutics Ltd Tetracyclic compounds for use in antibody-drug conjugates for the treatment of cancer
WO2025242908A2 (en) * 2024-05-24 2025-11-27 Genome Therapeutics Ltd Novel compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003136A1 (en) 1990-08-24 1992-03-05 Abbott Laboratories Quinobenzoxazine, quinobenzothiazine, and pyrido-acridine antineoplastic agents
US6821969B2 (en) * 2001-02-13 2004-11-23 Pharmacia & Upjohn Company Thioxazinoquinolones as antiviral agents
US7141565B1 (en) * 2003-04-07 2006-11-28 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808070A1 (de) * 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
DE3267485D1 (en) 1981-02-18 1986-01-02 Nippon Shinyaku Co Ltd Substituted carboxylic acid derivatives
ZA852769B (en) * 1984-04-26 1985-11-27 Abbott Lab Benzothiazolo-quinoline antibacterial compounds
ZA852802B (en) * 1984-04-26 1985-11-27 Abbott Lab Benzoxazolo-quinoline antibacterial compounds
US4528285A (en) * 1984-04-26 1985-07-09 Abbott Laboratories Methylenedioxy quino-benzothiazine derivatives
WO1989012055A1 (fr) 1988-06-08 1989-12-14 Kyorin Pharmaceutical Co., Ltd. Agent antitumoral
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
JPH04117388A (ja) * 1990-09-07 1992-04-17 Hokuriku Seiyaku Co Ltd チアゾロキノリン―４―カルボン酸誘導体
US5646163A (en) * 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
GB9402275D0 (en) * 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6699989B1 (en) 2000-08-28 2004-03-02 B. Vithal Shetty Antiviral and antimicrobial guanidine or biguanidine derivatives
DE60113450T2 (de) * 2000-12-14 2006-07-13 The Procter & Gamble Company, Cincinnati Antimikrobielle chinolone
US6900224B2 (en) 2002-07-31 2005-05-31 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
CN104324029A (zh) * 2004-03-15 2015-02-04 逊尼希思制药公司 Sns-595及其使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003136A1 (en) 1990-08-24 1992-03-05 Abbott Laboratories Quinobenzoxazine, quinobenzothiazine, and pyrido-acridine antineoplastic agents
US6821969B2 (en) * 2001-02-13 2004-11-23 Pharmacia & Upjohn Company Thioxazinoquinolones as antiviral agents
US7141565B1 (en) * 2003-04-07 2006-11-28 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs

Also Published As

Publication number Publication date
MX2007003282A (es) 2007-10-16
JP2008513485A (ja) 2008-05-01
AU2005286965A1 (en) 2006-03-30
AU2005286965B2 (en) 2009-10-22
US20060074089A1 (en) 2006-04-06
IL181857A0 (en) 2007-07-04
US7816406B2 (en) 2010-10-19
CA2580749C (en) 2014-01-28
KR20070085264A (ko) 2007-08-27
CA2580749A1 (en) 2006-03-30
WO2006034113A3 (en) 2006-08-24
WO2006034113A2 (en) 2006-03-30
BRPI0515319A (pt) 2008-07-22
EP1802306A2 (en) 2007-07-04
NZ553746A (en) 2010-06-25

Similar Documents

Publication Publication Date Title
KR100989029B1 (ko) 세포 증식 억제제로서의 퀴놀론 동족체
US20090215761A1 (en) Quinobenzoxazine analogs and methods of using thereof
RU2549895C2 (ru) Аналоги хинолона и относящиеся к ним способы
US7612063B2 (en) Substituted quinobenzoxazine analogs
US20100063046A1 (en) Tetracyclic imidazole analogs
US7507727B2 (en) Substituted quinobenzoxazine analogs and methods of using thereof
US7354916B2 (en) Substituted quinobenzoxazine analogs
RU2349586C2 (ru) Аналоги хинолона
ZA200508093B (en) Substituted quinobenzoxazine analogs

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20131015

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20131015